Invivyd's VYD2311 Shows Superior Safety vs mRNA Vaccine, BLA Filing Planned
IVVD has more than doubled off its 52-week low of $0.528 on elevated volume (2.6× avg).
Summary
Invivyd announced positive topline results from its Liberty Phase 3 study, showing VYD2311 has superior safety and tolerability compared to mRNA-based COVID-19 vaccines. The company also plans to submit a Biologics License Application (BLA) to the FDA via the accelerated approval pathway. This is a major development for a company facing going concern doubts, a Nasdaq delisting notice, and the loss of its only authorized product's EUA. The positive data and regulatory path forward could significantly change the company's outlook. Investors should watch for the actual BLA submission and any FDA feedback.
At the time of this announcement, IVVD was trading at $1.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $280M. The 52-week trading range was $0.53 to $3.07. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.